Suboxone.com - Informational Websites

The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe® Acrobat® Reader®. If you already have Adobe Acrobat Reader installed click "View PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.

You are leaving Suboxone.com. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Clicking on "Continue" will take you to a website that is outside the control of Reckitt Benckiser Pharmaceuticals. You are solely responsible for your interactions with such websites.

Links are provided as a public service and for informational purposes only.

You are leaving Suboxone.com and are being redirected to HereToHelpProgram.com, the website that contains the information you requested. HereToHelpProgram.com and Suboxone.com are owned and operated by Reckitt Benckiser Pharmaceuticals Inc.

As always, your information will not be sold or shared with anyone. See our privacy policy for more information.

IMPORTANT INFORMATION:

On December 8, 2006, Federal legislation was passed allowing physicians to treat up to 100 opioid-dependent patients with Suboxone at any given time—a significant increase from the previous limit of 30 patients.

There may be doctors in your area participating in a study to measure opioid dependence treatment outcomes. Patients who meet the eligibility requirements to participate in this study can receive up to $225 in compensation to complete surveys about their treatment.

NOTE: This study is only open to patients not currently under the care of a physician for opioid dependence and are seeking a treatment provider.

Please call 1-866-455-8876 between 9:00 AM to 7:30 PM EST to get more information.

Seeking Information for myself or loved one

Here to Help™ provides support throughout treatment. Whether you're seeking treatment information or you're already in treatment, we can provide resources that can help you make treatment a success.

HereToHelpProgram.com respects your privacy.
Read our Privacy Policy for more information.

If you can read this, then your browser cannot interpret Javascript. To take full advantage of what this website has to offer, please make sure that you have Javascript enabled in your browser preferences, or update to a browser that supports Javascript. Thank you.

Prescribing Information -- Site Map

Support That Helps Patients Stay In Treatment

Learn how patients can benefit from this free support system

Become a Here to Help Provider

Learn how becoming a provider can benefit you and your practice

Request a Consultation
With a Clinical Liaison

Personalized assistance
& information for your
practice

Opioid Dependence
Screening Kit

A free kit to help you identify opioid-dependent patients and make a difference in their lives today

Physician Locator

Learn how to be listed as a SUBOXONE prescriber

Order Printed Copies

To order printed copies of any of these materials call 1-877-SUBOXONE (1-877-782-6966)

Informational Websites

American Academy of Addiction Psychiatry (AAAP)
345 Blackstone Boulevard
2nd Floor - RCH
Providence, RI 02906
Phone: (401) 524-3076
Fax: (401) 272-0922
www.aaap.org

American Osteopathic Academy of Addiction Medicine (AOAAM)
5550 Friendship Blvd, Suite 300
Chevy Chase, MD
Phone: (301) 968-4160
Fax: (301) 968-4199
www.aoa-net.org

American Society of Addiction Medicine (ASAM)
4601 North Park Avenue, Arcade Suite 101
Chevy Chase, MD 20815
Phone: (301) 656-3920
Fax: (301) 656-3815
www.asam.org

Center for Substance Abuse Treatment (CSAT)
A Division of the Substance Abuse and Mental Health Services Administration
Room 12-105 Parklawn Building
5600 Fishers Lane
Rockville, MD 20857
Phone: (301) 443-5700
Fax: (301) 433-8751
www.samhsa.gov

Partnership for a Drug-Free America
405 Lexington Avenue, Suite 1601
New York, NY 10174
Phone: (212) 922-1560
Fax: (212) 922-1570
www.drugfree.org

National Alliance of Advocates for Buprenorphine Treatment (NAABT)
P.O. Box 333
Farmington CT 06034
Fax: (860) 269-4391
www.naabt.org

National Institute on Drug Abuse (NIDA)
A Division of the National Institutes of Health
6001 Executive Boulevard, Room 5213
Bethesda, MD 20892
Phone: (301) 443-1124
www.nida.nih.gov

Physician Clinical Support System (PCSS)
Funded by SAMHSA, administered by ASAM
PCSSproject@asam.org
Phone: (877) 630-8812
Fax: (301) 576-5156

Home -- About SUBOXONE -- Here to Help -- Treatment -- Certification -- Pharmacists -- Counselors -- Nurses -- Resources

SUBOXONE^®, SUBUTEX^®, and Here to Help^® are registered trademarks of Reckitt Benckiser Healthcare (UK) Ltd.

Important Safety Information

SUBOXONE^® (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets) (CIII) is indicated for the treatment of opioid dependence.

It is extremely dangerous to self-administer non-prescribed benzodiazepines or other depressants while taking SUBOXONE. A serious overdose and death may occur if benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol are taken at the same time as SUBOXONE.

SUBOXONE has potential for abuse and produces dependence of the opioid type, with a milder withdrawal syndrome than full agonists.

Cytolytic hepatitis and hepatitis with jaundice have been observed in the addicted population receiving buprenorphine.

Allergic reactions including bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients taking buprenorphine.

There are no adequate and well-controlled studies of SUBOXONE (a Category C medication) in pregnancy.

Caution should be exercised when driving cars or operating machinery.

Always store buprenorphine-containing medications safely and out of the reach and sight of children. Destroy any unused medication appropriately.

The most commonly reported adverse events with SUBOXONE include: headache (36%, placebo 22%), withdrawal syndrome (25%, placebo 37%), pain (22%, placebo 19%), insomnia (14%, placebo 16%), nausea (15%, placebo 11%), and sweating (14%, placebo 10%). Please see full Prescribing Information for a complete list.

To report an adverse event caused by taking SUBOXONE, please call 1-877-782-6966. You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information